Proteostasis therapeutics, inc. (PTI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

-

5,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

8,384

5,558

5,044

4,663

4,312

0

0

0

Operating expenses:
Research and development

42,689

52,319

56,935

62,381

58,060

50,312

48,877

46,180

48,946

53,654

51,833

48,157

40,191

33,959

29,285

26,325

24,897

22,524

0

0

0

General and administrative

13,479

13,835

14,559

15,555

15,830

15,710

14,777

13,368

12,313

11,660

12,011

12,536

12,749

11,880

10,451

8,708

7,302

6,322

0

0

0

Total operating expenses

56,168

66,154

71,494

77,936

73,890

66,022

63,654

59,548

61,259

65,314

63,844

60,693

52,940

45,839

39,736

35,033

32,199

28,846

0

0

0

Loss from operations

-56,168

-61,154

-66,494

-71,881

-66,992

-63,182

-59,192

-54,590

-55,997

-59,973

-56,065

-52,750

-44,693

-37,455

-34,178

-29,989

-27,536

-24,534

0

0

0

Interest income

943

1,093

1,220

1,167

1,064

872

656

640

615

641

705

586

437

0

0

0

-

-

-

-

-

Interest expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

599

0

0

0

Other income, net

643

936

1,105

950

704

478

180

68

20

-100

-65

-78

-81

-23

676

433

643

93

0

0

0

Net loss

-54,585

-59,125

-64,169

-69,764

-65,224

-61,832

-58,356

-53,882

-55,362

-59,432

-55,425

-52,242

-44,337

-37,232

-33,446

-29,725

-27,291

-25,040

0

0

0

Accruing dividends on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

1,378

4,404

6,863

9,015

9,724

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-38,610

-37,133

-35,698

-26,577

-25,035

0

0

0

Net loss per share—basic and diluted

-0.19

-0.23

-0.25

-0.39

-0.28

-0.36

-0.50

-0.43

-0.32

-0.51

-0.56

-0.68

-0.60

-0.38

-0.54

-0.47

-0.87

-

-

-

-

Weighted average common shares outstanding—basic and diluted

52,146

51,351

51,099

51,097

50,976

46,687

36,694

36,009

34,474

26,465

25,093

25,040

25,020

24,975

20,073

19,139

10,766

-

-

-

-

Other comprehensive income:
Unrealized gain on investments

25

6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-54,560

-59,119

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-